Surmodics | SRDX - Operating Profit


Surmodics reported $58K in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Align Technology USD 224.71M 40.06M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Artivion USD 4.79M 6.85M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Boston Scientific USD 1.24B 203M Dec/2025
EDAP TMS EUR -4.92M 843K Sep/2025
Edwards Lifesciences USD 370.3M 54.8M Dec/2025
Haemonetics USD 67.4M 8.9M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Merit Medical Systems USD 54.2M 11.58M Dec/2025
Mesa Laboratories USD 5.78M 2.27M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Option Care Health USD 91.5M 6.99M Dec/2025
Stryker USD 1.97B 609M Dec/2025
Surmodics USD 58K 5.7M Jun/2025
Trinity Biotech USD -509K 6.27M Sep/2025